Trial Profile
Evaluating the Tolerability and Safety Profile of Switching From Rituximab to Ocrelizumab: A Real World Evaluation of Patients With Relapsing Forms of Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Ocrelizumab (Primary) ; Rituximab
- Indications Multiple sclerosis
- Focus Adverse reactions
- 13 Jan 2020 Status changed from recruiting to completed.
- 16 Apr 2019 Planned End Date changed from 1 Jan 2019 to 30 May 2019.
- 16 Apr 2019 Planned primary completion date changed from 1 Jan 2019 to 30 May 2019.